We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current PYC market cap is 5.86B. The company's latest EPS is AUD -0.0081 and P/E is -154.32.
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 2.46M | 3.13M | 16.04M | 15.81M | 22.06M |
| Operating Income | -7.24M | -18.7M | -14.16M | -23.36M | -38.36M |
| Net Income | -6.82M | -17.77M | -13.86M | -22.79M | -37.73M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 31.55M | 57.94M | 45.35M | 37.17M | 91.24M |
| Total Liabilities | 1.35M | 4.02M | 5.15M | 8.72M | 10.18M |
| Total Equity | 30.2M | 53.92M | 40.2M | 28.44M | 81.06M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -5.75M | -11.79M | -21.78M | -24.42M | -38.59M |
| Investing | -13.77M | -15.52M | 32.68M | -477k | -307k |
| Financing | 25.11M | 38.56M | -182k | 11.44M | 90.19M |
| Market Cap | 5.86B |
| Price to Earnings Ratio | -154.32 |
| Price to Sales Ratio | 265.96 |
| Price to Cash Ratio | 87.41 |
| Price to Book Ratio | 71.96 |
| Dividend Yield | - |
| Shares Outstanding | 4.67B |
| Average Volume (1 week) | 312.84k |
| Average Volume (1 Month) | 406.57k |
| 52 Week Change | 1,529.87% |
| 52 Week High | 2.00 |
| 52 Week Low | 0.076 |
| Spread (Intraday) | 0.03 (1.95%) |
| Company Name | PYC Therapeutics Limited |
| Address |
suite 8 perth, western australia 6053 |
| Website | https://www.pyctx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
